442 related articles for article (PubMed ID: 20378167)
1. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
Park K; Lee MY; Kim KS; Hahn SK
Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
[TBL] [Abstract][Full Text] [Related]
2. Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis.
Park K; Hong SW; Hur W; Lee MY; Yang JA; Kim SW; Yoon SK; Hahn SK
Biomaterials; 2011 Jul; 32(21):4951-8. PubMed ID: 21481451
[TBL] [Abstract][Full Text] [Related]
3. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
Jiang G; Park K; Kim J; Kim KS; Hahn SK
Mol Pharm; 2009; 6(3):727-37. PubMed ID: 19178144
[TBL] [Abstract][Full Text] [Related]
4. Target-specific gene silencing of layer-by-layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex.
Lee MY; Park SJ; Park K; Kim KS; Lee H; Hahn SK
ACS Nano; 2011 Aug; 5(8):6138-47. PubMed ID: 21739990
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA.
Jiang G; Park K; Kim J; Kim KS; Oh EJ; Kang H; Han SE; Oh YK; Park TG; Kwang Hahn S
Biopolymers; 2008 Jul; 89(7):635-42. PubMed ID: 18322932
[TBL] [Abstract][Full Text] [Related]
6. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
[TBL] [Abstract][Full Text] [Related]
7. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.
Huang HY; Kuo WT; Chou MJ; Huang YY
J Biomed Mater Res A; 2011 Jun; 97(3):330-8. PubMed ID: 21465641
[TBL] [Abstract][Full Text] [Related]
9. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
Kim SH; Lee SH; Tian H; Chen X; Park TG
J Drug Target; 2009 May; 17(4):311-7. PubMed ID: 19242850
[TBL] [Abstract][Full Text] [Related]
11. Intracellular trafficking and unpacking of siRNA/quantum dot-PEI complexes modified with and without cell penetrating peptide: confocal and flow cytometric FRET analysis.
Lee H; Kim IK; Park TG
Bioconjug Chem; 2010 Feb; 21(2):289-95. PubMed ID: 20078095
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate.
Kim SH; Mok H; Jeong JH; Kim SW; Park TG
Bioconjug Chem; 2006; 17(1):241-4. PubMed ID: 16417275
[TBL] [Abstract][Full Text] [Related]
13. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
[TBL] [Abstract][Full Text] [Related]
14. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
15. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
Bioconjug Chem; 2008 Nov; 19(11):2156-62. PubMed ID: 18850733
[TBL] [Abstract][Full Text] [Related]
16. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo.
Xia W; Wang P; Lin C; Li Z; Gao X; Wang G; Zhao X
J Control Release; 2012 Feb; 157(3):427-36. PubMed ID: 22036880
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
Murata N; Takashima Y; Toyoshima K; Yamamoto M; Okada H
J Control Release; 2008 Mar; 126(3):246-54. PubMed ID: 18215787
[TBL] [Abstract][Full Text] [Related]
18. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
19. Reducible poly(amido ethylenimine) directed to enhance RNA interference.
Hoon Jeong J; Christensen LV; Yockman JW; Zhong Z; Engbersen JF; Jong Kim W; Feijen J; Wan Kim S
Biomaterials; 2007 Apr; 28(10):1912-7. PubMed ID: 17218006
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.
Tao J; Tu YT; Huang CZ; Feng AP; Wu Q; Lian YJ; Zhang LX; Zhang XP; Shen GX
Br J Dermatol; 2005 Oct; 153(4):715-24. PubMed ID: 16181451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
